Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
The Lancet Oncology.
Times cited: 1
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
International Journal of Radiation Oncology Biology Physics.
Times cited: 2
Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology.
Times cited: 42
Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER trial.
Journal of Cancer.
Times cited: 32